Click on image to view larger version.

Figure 2 Changes in OxLDL, Lp-PLA2, and ApoB-100 After Statin Therapy

(A) Changes in oxidized low-density lipoprotein cholesterol (OxLDL) after statin therapy as measured by the Mercodia assay. Mean Mercodia OxLDL (antibody 4E6) levels (mg/dl) at baseline and 16 weeks in placebo-, pravastatin 40 mg/day (prava40)-, atorvastatin 10 mg/day (atorva10)-, and atorvastatin 80 mg/day (atorva80)-treated groups. (B) Changes in lipoprotein-associated phospholipase A2 (Lp-PLA2) mass after statin therapy. Mean Lp-PLA2 mass (ng/ml) at baseline and 16 weeks in placebo-, prava40-, atorva10-, and atorva80-treated groups. (C) Changes in apolipoprotein B-100 particle (apoB-100) after statin therapy. Mean apoB-100 levels (mg/dl) at baseline and 16 weeks in placebo-, prava40-, atorva10-, and atorva80-treated groups.